CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI) (CATCH-AMI)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01905475 |
Recruitment Status :
Completed
First Posted : July 23, 2013
Last Update Posted : June 10, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Large Reperfused ST-Elevation Myocardial Infarction | Drug: POL6326 Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction |
Study Start Date : | July 2013 |
Actual Primary Completion Date : | October 2015 |
Actual Study Completion Date : | June 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: POL6326
POL6326 intravenous infusion
|
Drug: POL6326 |
Placebo Comparator: Placebo
Placebo intravenous infusion
|
Drug: Placebo |
- Change in LVEF (left ventricular ejection fraction) as determined by MRI [ Time Frame: 4 months ]Difference in LVEF from baseline (after STEMI and stent procedure, before infusion of drug or placebo) and after 4 months
- Additional measures of cardiovascular function [ Time Frame: 4 months ]Using MRI the following parameters will also be determined: infarct size, LV volumes, regional LV function. Plasma BNP (brain natriuretic peptide) will also be determined.
- Mobilization of stem and progenitor cells [ Time Frame: 2 days ]Time dependent measurement of stem and progenitor cells during and after infusion of POL6326
- Pharmacokinetic outcome [ Time Frame: 2 days ]Measurement of plasma concentrations of POL6326 at predose and several time points after infusion.
- Safety of POL6326 by intravenous infusion [ Time Frame: 12 months ]Safety as measured by incidence, type and severity of adverse events (Major Adverse Cardiovascular Events (MACE), Arrhythmia)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with symptoms suggestive of an acute MI with ST-segment elevation or new left bundle-branch block and a rise or fall in cardiac necrosis markers.
- Patients must be scheduled to undergo coronary angiography for the purposes of primary PCI (percutaneous coronary intervention) culminating in successful stent implantation.
- Age between 18 and 80 years. Male and WOCBP (women of child bearing potential) willing to use highly effective methods of contraception from the time of first dose until 3 months after the last dose of the drug.
- Markedly reduced LVEF at baseline cardiac MRI.
- No previous occurrence of Myocardial Infarction.
- Estimated glomerular filtration rate (eGFR) equal or higher than 40 mL/minute prior to MRI.
- Signed Informed Consent.
Exclusion Criteria:
- Evidence of multi-vessel coronary artery disease likely to require repeat PCI or coronary artery bypass grafting within 4 months.
- Pulmonary oedema or cardiogenic shock requiring intubation or mechanical support at the time of the planned baseline MRI.
- Fitted with a non-MRI-compatible cardiac pacemaker or implantable cardioverter defibrillator, or expected to require such a device within 4 months after randomisation.
- Terminal illness or malignant disease.
- Advanced hepatic disease.
- Diagnosis of severe obesity which precludes MRI assessments.
- Claustrophobia.
- Acute systemic infection or fever.
- Anemia (where hemoglobin levels are <10 g/dL), thrombocytopenia (platelet count <100000/μL) or coagulopathy.
- History of multiple drug allergies or with a known allergy to the drug class of CXCR4 antagonists.
- Pregnancy or females of childbearing potential who are not using double contraception
- Known history of human immunodeficiency virus (HIV) infection, chronic hepatitis B or hepatitis C infection or significant active chronic inflammatory disease that requires immunosuppressive medication or regular systemic corticosteroids.
- Patients who have participated in any investigational drug or device trial within 30 days prior to signing informed consent.
- Patients who are unwilling or unable to abide by the study requirements.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01905475
Principal Investigator: | Kai C. Wollert, MD | Hannover Medical School |
Responsible Party: | Polyphor Ltd. |
ClinicalTrials.gov Identifier: | NCT01905475 |
Other Study ID Numbers: |
POL6326-POL-006 |
First Posted: | July 23, 2013 Key Record Dates |
Last Update Posted: | June 10, 2016 |
Last Verified: | June 2016 |
STEMI AMI repair |
Myocardial Infarction ST Elevation Myocardial Infarction Infarction Ischemia Pathologic Processes |
Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases |